Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled study of Shenqi balance Capsule in non-proliferative diabetic retinopathy
CTR20252767Phase 3Active
- Sponsor
- 西安乐健生物科技
- Start
- Sep 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetic retinopathy (DR) and nonproliferative diabetic retinopathy (NPDR) comparing Shenqi balance Capsule with Placebo comparator (2 arms). Primary endpoint: Change from baseline in best-corrected visual acuity after 24 weeks of treatment. Started Sep 2025; status: active.
02
Drugs
Shenqi Balance Capsule
03
Conditions
diabetic retinopathy (DR)nonproliferative diabetic retinopathy (NPDR)
Beyond the preview
Go deeper on CTR20252767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252767.